Patients with wild-type PIK3CA had better OS (HR 0.161, p = 0.010) and disease-free survival (DFS) (HR 0.376, p = 0.069) than those with PIK3CA mutations in HER2− breast cancer patients. This evidence concerns the gene PIK3CA and breast cancer.